Literature Analysis of Artificial Intelligence in Biomedicine

Review

Tim Hulsen¹

Affiliation:
¹Department of Hospital Services & Informatics, Philips Research, Eindhoven, The Netherlands

Abstract

Artificial Intelligence (AI) refers to the simulation of human intelligence in machines, using machine learning, deep learning and neural networks. AI enables machines to learn from experience and perform human-like tasks. The field of AI research has been developing fast over the past five to ten years, due to the rise of ‘big data’ and increasing computing power. In the medical area, AI can be used to improve diagnosis, prognosis, treatment, surgery, drug discovery, or other applications. Therefore, both academia and industry are spending a lot of time and money in AI. This review takes a look at the biomedical literature (in the PubMed and Embase databases) and does some interesting observations: AI is growing exponentially over the past few years; it is used mostly for diagnosis; COVID-19 is already in the top-5 of diseases studied using AI; the United States, China, United Kingdom, South Korea and Canada are publishing the most articles in AI research; MIT is the world’s leading university in AI research; and convolutional neural networks are by far the most popular deep learning algorithms at this moment. The expectation is that AI will keep on growing, in spite of stricter privacy laws, more need for standardization, bias in the data, and the need for building trust. In order for AI to succeed in making healthcare better, it should be fully integrated into the clinician’s workflow so that they can focus on the contact with their patients.

Keywords:
Artificial intelligence, machine learning, deep learning, neural networks, biomedicine, healthcare, medicine, literature, PubMed, Embase
Introduction

Artificial Intelligence (AI) refers to the simulation of human intelligence in machines. It includes techniques such as machine learning (ML), deep learning (DL) and neural networks (NN). AI makes it possible for machines to learn from experience and perform human-like tasks [1]. The field of AI research was born at a workshop at Dartmouth College in 1956, where the term “Artificial Intelligence” was invented by John McCarthy [2]. Progress was slow at first, until in the late 1990s and early 2000s, AI began to be used for logistics, data mining, medical diagnosis and other areas [3]. Over the past five to ten years this field has been developing fast due to computing power, especially in areas where large datasets are available to be mined, such as astronomy [4] or meteorology [5]. Biomedicine is such an area as well: many ‘big data’ projects are taking place [6], with an abundance of clinical data from electronic health record (EHR) systems, genomics data from whole genome sequencing (WGS) studies, and digital imaging data from magnetic resonance (MR), ultrasound (US) scanners and digital pathology systems. This kind of ‘wide’ (i.e. many parameters) as well as ‘long’ (i.e. many subjects) data [7] is particularly useful for AI algorithms, which need a lot of diverse data to avoid overfitting. Therefore, AI has many interesting applications in the medical area, whether it is for diagnosis, prognosis, treatment, surgery, drug discovery, or for other applications. For example, last year an antibiotic (halicin) was discovered using a deep learning algorithm [8]. Robots and telemedicine are being used to keep health workers safe during the COVID-19 pandemic [9]. And people with mental health issues can use therapeutic chatbots [10]. AI offers a broad range of possibilities in both academia and industry. Top hospitals such as the Mayo Clinic and the Cleveland Clinic [11] as well as large health-tech companies such as Philips [12], Siemens [13] and GE [14] invest a lot of time and money in data science and AI. Biotech companies such as BERG and pharma companies such as Takeda and are also using AI in their biomarker discovery [15] and drug discovery [16] pipelines. Google (by acquiring Fitbit) and Apple invest in AI in wearables that can track the health and lifestyle of the customers [17]. Microsoft has built a cloud service especially for storing and sharing healthcare data [18], just like Amazon [19] and Google [20]. Facebook has developed a tool called Preventive Health which connects people to health resources and checkup recommendations from health organizations [21]. This means that all five of the American “Big Tech” or “GAFAM” companies now have extended their products and services into the healthcare domain. And these products and service all include AI in
some form, changing healthcare in a way that has never been seen before. Some excellent reviews have been written already about how AI is changing medicine and healthcare [22; 23; 24; 25]. In this review we will take another approach: we will look at the current status of AI in the biomedical literature: what trends can be seen over time? What terms are related to AI? What diseases are studied using AI? What application areas are being researched? What countries are leading the way? What universities publish the most AI papers? What drugs are studied with AI? What drug or device manufacturers are using AI? Which AI algorithms are most popular over time? And so forth. We will also place the results in context: what do these trends mean and what developments could cause AI to stop growing at the current rate?
AI has, for a long time, been a promise of the future. When looking at the occurrence of the search term ‘artificial intelligence’ in the PubMed database (figure 1), there is a steady rise visible from 1980 to a plateau in the period 2005-2008, followed by a few years of decline. This decline might have been caused by the limited computation power at that time compared to now. According to Moore’s law [26], researchers nowadays have $2^7=128$ more computation power available than in 2007. In the 2000s, researchers could see the potential of AI, and were performing research in that area, but were still limited in its use. Since 2018, the occurrence of the search term ‘artificial intelligence’ shows a steep incline again. Apparently, computers are now fast enough to really make use of AI and to fulfill its promise. Related search terms such as ‘machine learning’, ‘deep learning’ and ‘neural network’ show an incline as well, especially since 2016.

**Figure 1.** Occurrence of four search terms related to Artificial Intelligence in the titles and/or abstracts in the PubMed database, as a percentage of the total of publications, for the period 1980-2020. Generated by the R package ‘easyPubMed’ [27].
Figure 2. Wordcloud of all titles, affiliations and abstracts of PubMed publications (until 2021-04-19) containing the keyword "artificial intelligence", generated by the R packages easyPubMed [27] and wordcloud [28].
Diseases studied with AI

When we look into the Embase database (Excerpta Medica database; a biomedical and pharmacological bibliographic database) and search for ‘artificial intelligence’, we get 41,161 results. Embase offers the option to look at the diseases mentioned in the publications. The top-20 of results is displayed in figure 3. This shows that COVID-19 is already on top, with ‘breast cancer’ on place 2, but also on place 14 (‘breast tumour’). ‘Pandemic’ is on place 3, probably because of COVID-19 as well. There are 8 oncological diseases, which might point to the complexity and heterogeneity of cancers, which need deep learning algorithms for proper classification. There are also 5 cardiovascular diseases, 3 brain disorders and 2 diabetic diseases.

Figure 3. Top-20 of diseases found in publications in the Embase database (until 2021-04-07) which also contain the term ‘artificial intelligence’.
Disease areas and application areas using AI

Using Embase, we can also look at disease areas in relation to application areas such as diagnosis, prognosis, treatment, surgery and drug discovery. Figure 4 shows the main five disease areas derived from the analysis of figure 3, subdivided into these 5 application areas. We used the ‘explosion’ option here, which includes all narrower (more specific) terms in the search query, so that they do not have to be entered individually [29]. AI seems to be used mostly within the field of oncology. In all disease areas, there seem to be more AI applications for diagnosis than for the other application areas. Publications around brain diseases are relatively often related to diagnosis (28.4% of the total), whereas publications around cancer are relatively often related to prognosis (73.1% of the total). Similar relationships can be found between diabetes and treatment (9.0%), cardiovascular diseases and surgery (12.0%) and COVID-19 and drug discovery (11.4%).

Figure 4. Occurrences of disease areas in combination with application areas, together with the search term ‘artificial intelligence’, in the Embase database (date of search query 2021-04-08).
Countries performing research in AI

With Embase, we can find out which countries perform the most research in the field of AI. Figure 5 shows all combinations of the search term ‘artificial intelligence’ and each of the names of the top-20 global economies in the ‘affiliation’ field. Not surprisingly, the top spots are taken by the USA and China (the #1 and #2 economies), followed at a distance by the UK, South Korea and Canada (the #5, #10 and #9 economies). The bottom spots are taken by Saudi Arabia (25 publications) and Indonesia (22 publications). These findings are not much different from the Nature Index analysis of 2020 [30], in which the USA and China are leading the way as well. There are some differences though: in the Nature Index, the #3 and #5 spot are taken by Germany and Japan, whereas they are only #9 and #7 in Embase. This might be caused by the smaller number of journals covered by the Nature Index analysis (only 82 top journals), the shorter time period (2015-2019) and/or a different query used to search for AI publications. It should be noted as well that this analysis only includes the search term ‘artificial intelligence’ itself, while publications around AI might use terms such as ‘deep learning’ and ‘neural networks’ instead.

Figure 5. Occurrence of the search term ‘artificial intelligence’ in combination with any of the top-20 global economies in the ‘affiliation’ field, in the Embase database (date of search query 2021-04-28).
Universities performing research in AI

We can also investigate which universities perform the most research in the field of AI. Figure 6 shows all combinations of the search term ‘artificial intelligence’ and each of the names of the top-20 universities (taken from the Times Higher Education World University Rankings [31]) in the ‘affiliation’ field. The #1 spot is taken by the Massachusetts Institute of Technology (MIT) with 1283 publications, and the #2 is Stanford University with 747 publications. Indeed, MIT has developed several initiatives in AI, such as the Computer Science & Artificial Intelligence Lab (CSAIL) [32], and Stanford University is the employer of some of the world’s AI experts such as Andrew Ng, who is also one of the co-founders of Coursera and DeepLearning.ai [33]. Third place is for the University of Toronto (UoT) with 534 publications. UoT is located in the region with the highest concentration of AI startups in the world, and has started the University of Toronto Artificial Intelligence (UofT AI) Group [34]. The world’s top university according to this list, the University of Oxford, is only on the sixth spot when it comes to AI. The California Institute of Technology (Caltech) has only 71 publications with the search term ‘artificial intelligence’.

Figure 6. Occurrence of the search term ‘artificial intelligence’ in combination with any of the top-20 universities in the ‘affiliation’ field, in the Embase database (date of search query 2021-04-28).
Drugs studied with AI

Embase also includes drug trade names in their database. Figure 7 shows the prevalence of these drug names together with the search term ‘artificial intelligence’. The number one spot is for Herceptin, the brand name of the monoclonal antibody Trastuzumab, which is used to treat breast cancer and stomach cancer. The number two spot is for Aspirin, the popular medication used to reduce pain, fever and inflammation. The number thee spot is shared by two drugs. FK-506, also known as Tacrolimus and fujimycin, is sold under the brand names Protopic and Prograf, and is an immunosuppressive drug. SB 203580 is a selective inhibitor of cytokine suppressive binding protein/p38 kinase. One of the number five spots is taken by GS-5734, which is also known as Remdesivir, a drug that was used as treatment during the COVID-19 pandemic. Indeed, all four publications with ‘GS-5734’ and ‘artificial intelligence’ are about COVID-19. The list also includes three chemotherapy medications used to treat cancer (Adriamycin, Gleevec and Taxol), one other cancer medication (Iressa) and an iodinated contrast medium for X-ray imaging (Ultravist). It should be noted that overall numbers for drug data in Embase are quite low.

![Drugs in 'artificial intelligence' publications](image-url)

**Figure 7.** Top-10 of drugs found in publications in the Embase database (until 2021-04-19) which also contain the term ‘artificial intelligence’.
Drug manufacturers using AI

We can also have a look at the manufacturing companies of the drugs mentioned in the previous section (figure 8). This shows us that Sigma-Aldrich, currently known as MilliporeSigma and part of Merck, is on top of the list, followed by larger companies such as Pfizer, Bayer, GlaxoSmithKline (GSK), Hoffmann La-Roche, Novartis and Merck. The number 4, Sigma, is MilliporeSigma’s main biochemical supplier. MilliporeSigma’s chemicals are apparently being used a lot in scientific research; in search queries without ‘artificial intelligence’, ‘Sigma’ and ‘Sigma-Aldrich’ are on top of the list as well. Two other companies in the top-10 are Selleck (#5), an American chemicals supplier, and Bracco (#10), an Italian healthcare and pharma company. Some of the largest pharma companies are missing on this list, such as Johnson & Johnson, Sanofi, AbbVie and Takeda.

Figure 8. Top-10 of drug manufacturers found in publications in the Embase database (until 2021-04-19) which also contain the term ‘artificial intelligence’.
Device manufacturers using AI

When looking at device manufacturers using AI in biomedical publications (figure 9), Siemens takes the top spot with 149 publications. Siemens is also on the #7 (‘Siemens Healthcare’) and #9 (‘Siemens Healthineers’) spot, and even occurs eight times in the complete list. GE takes the #2 (‘GE Healthcare’) and #5 (‘General Electric’) spots and is mentioned seven times in total. Philips takes the #3 (‘Philips’) and #13 (‘Philips Healthcare’) place and is included in the list for seven times as well. Medtronic is another medical device company that is in the list (#12). Other companies include genomics companies such as Affymetrix and Illumina, but also imaging companies such as Olympus, Canon and Toshiba. Thermo Fisher Scientific and Agilent are producers of scientific instrumentation and software. Heidelberg Engineering is an Ophthalmology company. Microsoft is a multinational computer company that is also getting more active in the healthcare arena nowadays, just like its competitors Apple, Google and Amazon (which are not present in this top-20). Varian Medical Systems is a radiation oncology treatments and software maker. MathWorks is the creator of software such as MATLAB and Simulink, which support data analysis and simulation. Topcon is a manufacturer of optical equipment for ophthalmology and surveying.

![Device manufacturers in 'artificial intelligence' publications](image-url)

**Figure 9.** Top-20 of device manufacturers found in publications in the Embase database (until 2021-04-19) which also contain the term ‘artificial intelligence’.
AI algorithms

The Embase database also enables us to have a look at the use of several deep learning algorithms over time. We adapted the top-10 list found at [35] and checked their occurrence in biomedical publications. These 10 algorithms are:

1) Convolutional Neural Network (CNN, or ConvNet): a deep learning algorithm which can take in an input image, assign importance to various aspects/objects in the image and be able to differentiate one from the other. The architecture of a CNN is analogous to the neurons in the human brain. The first ever CNN was the 'Neocognitron' by Kunihiko Fukushima in 1980 [36].

2) Long Short-Term Memory Network (LSTM): an artificial recurrent neural network architecture (see #3) with feedback connections. It was proposed by Hochreiter and Schmidhuber in 1997 [37].

3) Recurrent Neural Network (RNN): a class of artificial neural networks where connections between nodes form a directed graph along a temporal sequence. This allows it to exhibit temporal dynamic behavior. RNNs are based on David Rumelhart's work from 1986 [38].

4) Generative Adversarial Network (GAN): a class of machine learning frameworks designed by Ian Goodfellow et al. in 2014 [39]. Two neural networks contest with each other in a zero-sum game. Given a training set, this technique learns to generate new data with the same statistics as the training set.

5) Radial Basis Function Network (RBFN): an artificial neural network that uses radial basis functions as activation functions. The network’s output is a linear combination of radial basis functions of the inputs and neuron parameters. RBFNs were introduced by Broomhead and Lowe in 1988 [40].

6) Multilayer Perceptron (MLP): a class of feedforward artificial neural network, composed of multiple layers of perceptrons. Its multiple layers and non-linear activation distinguish MLP from a linear perceptron, which was invented by Frank Rosenblatt as early as 1957 [41].

7) Self-Organizing Map (SOM): a type of artificial neural network that is trained using unsupervised learning to produce a low-dimensional, discretized representation of the input space of the training samples (called a map) and is therefore a method to do dimensionality reduction. Invented by Teuvo Kohonen in 1982 [42].
8) Deep Belief Network (DBN): a generative graphical model, or alternatively a class of deep neural network, composed of multiple layers of latent variables, with connections between the layers but not between units within each layer. DBNs were invented by Larochelle et al. in 2007 [43].

9) Restricted Boltzmann Machine (RBM): a generative stochastic artificial neural network that can learn a probability distribution over its set of inputs. RBMs were initially invented under the name ‘Harmonium’ by Paul Smolensky in 1986 [44]. Named after the Austrian physicist and philosopher Ludwig Boltzmann.

10) Autoencoder: an unsupervised artificial neural network that learns how to efficiently compress and encode data, and then learns how to reconstruct the data back from the reduced encoded representation to a representation that resembles the original input as much as possible. Autoencoders were introduced by Rumelhart et al. in 1986 [45], just like RNNs.

The first occurrence of any of the terms in the Embase database was ‘Multilayer Perceptron’ (MLP) in 1988, in the paper ‘Auto-association by multilayer perceptrons and singular value decomposition’ [46] by Bourlard & Kamp from the Philips Research Laboratory in Brussels, Belgium. The following years there was some use of RNNs, RBFNs, MLPs and SOMs, but never more than 100 publications per year in total. Only since 2015 has the use of these deep learning algorithms really taken off, which can be seen in figure 10. Especially CNNs are getting very popular, with 5214 publications in 2020, followed by RNNs (1081 publications in 2020). CNNs are mostly used for image analysis and classification [47]. RNNs can be used for predictions based on time series (longitudinal data) [48]. Autoencoders are on third place in 2020 with 565 publications. MLPs are still popular as well (519 publications in 2020). GANs have only been around in the biomedical literature since 2017, despite its first publication in 2014 [39]. They can be used to create synthetic data based on real data [49], which is particularly useful in cases where the real data cannot be analyzed because of privacy regulations.
Figure 10. Occurrence of ten deep learning algorithms in the titles and/or abstracts in the Embase database, for the period 2015-2020. The vertical axis is displayed on a base-2 log scale.
Discussion

This review shows the wide range of AI in biomedicine, and it shows the exponential rate at which it is growing. Now that computers are fast enough to execute complex algorithms, AI is expected to keep on growing. Heterogeneous diseases such as cancer can profit enormously from deep learning algorithms to properly stratify patient cohorts [50], and drugs and biomarkers will be found much more easily using AI [51]. AI will therefore be a crucial component in enabling precision medicine. However, there are also recent developments that might hinder the rise of AI. For example, stricter privacy regulations such as the GDPR [52] make it more difficult to store and analyze personal data, as it requires researchers to state the purpose of the data collection upfront, gives data subjects the right to withdraw their data at any time, etc.. A possible solution here is the use of a federated setup, in which data stay at the source, AI algorithms are run locally on the data, and only the results are then brought together [53]. An example of this is the Personal Health Train initiative [18] in the Netherlands. Such a federated setup can be combined with multiparty homomorphic encryption, which is a synthesis between two novel advanced privacy-enhancing technologies: homomorphic encryption and secure multiparty computation [54]. This will provide a mathematical guarantee of privacy, ensuring that data can be considered anonymized. Moreover, federated learning is especially useful for the study of rare diseases, where each separate source might have too little cases to setup a study with enough statistical power [55]. Recently, the European Commission has also announced a set of regulations around the use of AI [56], defining some high-risk application areas of AI, under which some medical areas such as robot-assisted surgery. These high-risk application areas need to conform to a number of strict obligations around data quality, security, documentation, etcetera. Increasing use of AI also means that data should be machine-readable: data should adhere to standards around reproducibility and interoperability, such as the FAIR Guiding Principles [57] and other guidelines [58]. Data should be standardized using medical ontologies and vocabularies. Another issue that might affect the use of AI in biomedicine and healthcare is bias [59]: the output of an algorithm is shaped by the data that is fed into it. Therefore, if this data comes from only white males in the range of 50-65 years old, the algorithm will not create reliable results for Asian females in the range of 35-50 years old. Initiatives where data from all over the world (from both genders, many ethnicities, and many age groups) are combined into a central database produce results that are less biased. For example, in the field of prostate cancer such projects are Movember GAP3 ([60],
combining 25 different cohorts) and PIONEER ([61], with 32 public and private partners). Next to privacy regulations, machine-readability and bias, scientists should also work on building trust in AI. For non-experts, AI often seems like a black box where a lot of data go in and through some ‘black magic’ something comes out. This is only a logical effect of the mathematical complexity of most AI algorithms. Possible solutions therefore lie in explaining AI in a simple way [62], and also in anthropomorphizing AI algorithms and robots [63]. Finally, it is important to realize that AI is not meant to completely replace clinicians (at least, not in the near future), but to help them. Clinicians should be supported by AI in patient-centric solutions that can collaborate to reach precise diagnoses and more optimal treatment pathways. The solutions should be fully integrated into the clinician’s workflow. By using AI, clinicians should be able to focus more on other important tasks, such as the contact with their patients.
Competing interest statement

Dr. Hulsen is employed by Philips Research.

Acknowledgements

References


[41] F. Rosenblatt, The perceptron, a perceiving and recognizing automaton Project Para, Cornell Aeronautical Laboratory, 1957.


